Legend Biotech (LEGN) Tops Q2 EPS by 9c

Legend Biotech (NASDAQ: LEGN) reported Q2 EPS of $0.16, $0.09 better than the analyst estimate of $0.07. Revenue for the quarter came in at $387.5 million versus the consensus estimate of $362.81 million.

For earnings history and earnings-related data on Legend Biotech (LEGN) click here.

You May Also Be Interested In

• Stifel Reiterates Buy Rating on Analog Devices (ADI), Expects Solid Q3 Results
• Big Sky Industrial Inc. (BSIN) Reports In-Line Q2 EPS
• Protara Therapeutics, Inc. (TARA) Misses Q2 EPS by 2c